MiNK Therapeutics, Inc. (NASDAQ:INKT) Receives $35.00 Average Price Target from Brokerages

MiNK Therapeutics, Inc. (NASDAQ:INKT) has been assigned a consensus rating of “Hold” from the five brokerages that are covering the company, Marketbeat.com reports. One research analyst has rated the stock with a sell rating, two have issued a hold rating, one has given a buy rating and one has given a strong buy rating to the company. The average twelve-month price objective among brokers that have updated their coverage on the stock in the last year is $35.00.

INKT has been the subject of a number of recent research reports. Zacks Research upgraded shares of MiNK Therapeutics from a “strong sell” rating to a “hold” rating in a report on Monday, October 20th. Wall Street Zen cut MiNK Therapeutics from a “hold” rating to a “sell” rating in a research report on Saturday, December 20th. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of MiNK Therapeutics in a report on Wednesday, October 8th.

MiNK Therapeutics Stock Performance

Shares of INKT opened at $11.95 on Friday. The firm has a market cap of $56.05 million, a PE ratio of -3.94 and a beta of 0.35. The firm’s 50 day moving average price is $12.51 and its 200 day moving average price is $13.79. MiNK Therapeutics has a twelve month low of $4.56 and a twelve month high of $76.00.

MiNK Therapeutics (NASDAQ:INKT) last posted its earnings results on Friday, November 14th. The company reported ($0.65) EPS for the quarter, topping the consensus estimate of ($0.86) by $0.21. On average, sell-side analysts anticipate that MiNK Therapeutics will post -2.75 earnings per share for the current fiscal year.

MiNK Therapeutics Company Profile

MiNK Therapeutics, Inc is a clinical-stage biotechnology company developing exosome-based immunotherapies for the treatment of solid tumors. The company’s proprietary platform isolates and engineers naturally occurring extracellular vesicles, or exosomes, to deliver therapeutic payloads—such as mRNA, proteins and modulatory factors—directly into the tumor microenvironment. By leveraging the innate cell‐to‐cell communication properties of exosomes, MiNK aims to reprogram immune cells and overcome immune suppression within solid tumors.

MiNK’s preclinical pipeline features multiple lead candidates designed to repolarize tumor‐associated macrophages and boost T cell–mediated tumor clearance.